UCBJY Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 21:45):

Stats
Tagesvolumen	36 599.00
Durchschnittsvolumen	12 804.00
Marktkapitalisierung	25.23B
Last Dividend	$0.726 ( 2023-05-01 )
Next Dividend	$0 ( N/A )
P/E	70.72
ATR14	$0.189 (0.28%)

UCB SA Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

UCB SA Finanzdaten

Annual	2023
Umsatz:	$5.25B
Bruttogewinn:	$3.55B (67.50 %)
EPS:	$1.810

FY	2023
Umsatz:	$5.25B
Bruttogewinn:	$3.55B (67.50 %)
EPS:	$1.810

FY	2022
Umsatz:	$5.52B
Bruttogewinn:	$3.84B (69.64 %)
EPS:	$2.20

FY	2021
Umsatz:	$5.78B
Bruttogewinn:	$4.34B (75.11 %)
EPS:	$5.60

Financial Reports:

No articles found.

UCB SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.726 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

UCB SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.90 - Stable (2.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.663	2013-05-02
Last Dividend	$0.726	2023-05-01
Next Dividend	$0	N/A
Payout Date	2023-05-18
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$7.46	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.90
Div. Directional Score	8.72	--

Next Divdend (Est)
(2025-03-31)

$0.745 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
WJRYF	Ex Dividend Knight	2023-09-28	Annually	0.00%
MCBK	Ex Dividend Junior	2023-05-02	Annually	0.00%
CMSQY	Ex Dividend Knight	2023-08-22	Annually	0.00%
SOBS	Ex Dividend Knight	2023-06-29	Quarterly	0.00%
HCMLY	Ex Dividend Knight	2023-05-09	Annually	0.00%
AMNF	Ex Dividend King	2023-07-06	Quarterly	0.00%
NLCP	Ex Dividend Knight	2023-09-28	Quarterly	0.00%
CTUY	Ex Dividend Junior	2023-05-24	Annually	0.00%
THNPF	Ex Dividend Knight	2023-05-22	Annually	0.00%
IDCBY	Ex Dividend Junior	2023-07-06	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0656	1.500	8.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0331	1.200	8.90	10.00	[0 - 0.3]
returnOnEquityTTM	0.0571	1.500	-0.477	-0.715	[0.1 - 1]
payoutRatioTTM	0.490	-1.000	5.10	-5.10	[0 - 1]
currentRatioTTM	1.317	0.800	8.42	6.73	[1 - 3]
quickRatioTTM	0.839	0.800	9.77	7.81	[0.8 - 2.5]
cashRatioTTM	0.329	1.500	9.28	10.00	[0.2 - 2]
debtRatioTTM	0.196	-1.500	6.74	-10.00	[0 - 0.6]
interestCoverageTTM	4.50	1.000	9.45	9.45	[3 - 30]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0.338	-1.500	8.65	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.648	1.000	2.54	2.54	[0.2 - 0.8]
operatingProfitMarginTTM	0.120	1.000	9.59	9.59	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.328	1.000	9.29	9.29	[0.2 - 2]
assetTurnoverTTM	0.505	0.800	9.97	7.97	[0.5 - 2]
Total Score				12.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	22.86	1.000	7.79	0	[1 - 100]
returnOnEquityTTM	0.0571	2.50	-0.306	-0.715	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	2.34	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.26	2.00	8.25	10.00	[0 - 30]
payoutRatioTTM	0.490	1.500	5.10	-5.10	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.127	1.000	9.32	0	[0.1 - 0.5]
Total Score				4.90

UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.